Tirzepatide Research Guide: Dual Agonism at the Bench

Tirzepatide answered a question incretin researchers had asked for years: does adding GIP-receptor activity to GLP-1 agonism change outcomes? The published record said yes, emphatically — and dual agonism became a field overnight.

The twincretin design

Tirzepatide is a 39-amino-acid peptide engineered to activate both the GIP and GLP-1 receptors from a single molecule, with a fatty-diacid moiety for albumin binding. Its receptor bias actually favours GIP — a design detail that keeps receptor-pharmacology researchers busy.

Research applications

Signalling-bias studies, receptor-internalisation work and head-to-head comparisons with semaglutide dominate its literature. It slots between semaglutide and retatrutide in the one-two-three receptor ladder our comparison guide describes.

Handling and sourcing

Standard lyophilised protocol: -20°C powder, bacteriostatic-water reconstitution, 2-8°C solutions. We stock 5mg and 10mg vials, ≥99% HPLC-verified, batch documentation available on request, express from Australia.

Sourcing for a peptide business rather than a single bench? Our wholesale program supplies trade buyers Australia-wide from Australian-sourced, Australian-tested stock.

All compounds discussed are for in-vitro laboratory research only and are not for human or veterinary use.